| Active substance | daratumumab |
| Holder | Janssen-Cilag NV |
| Status | closed |
| Indication | in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic amyloid light chain (AL) amyloidosis |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 26/10/2023 |